Articles, guides, and regulatory updates from our community.
A 2026 study reveals significant geographic disparities in access to peptide-based sexual medicine therapies driven by state-level healthcare policies.
By Peptide Association Research Team
The regulatory landscape for compounded peptides has shifted dramatically. Here's what clinicians must understand about FDA enforcement, 503A/503B rules, and the bulk drug substance list.
By Peptide Association Editorial Team
How to evaluate compounding pharmacies, understand USP standards, interpret certificates of analysis, and ensure your patients receive safe, accurately dosed peptide products.
By Peptide Association Editorial Team